Idiopathic Inflammatory Myopathies Iim clinical trials

Explore recruiting idiopathic inflammatory myopathies iim clinical trials.

Recruiting idiopathic inflammatory myopathies iim studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Idiopathic Inflammatory Myopathies Iim trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Nipocalimab in Participants with Active Idiopathic Inflammatory Myopathies

Hungary, Poland, Czechia, Italy, Germany, France +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, randomized, open-label, controlled study to evaluate the efficacy and safety of rapcabtagene autoleucelversus comparator in participants with severe refractory idiopathic inflammatory myopathies

Spain, Germany, France, Netherlands, Italy, Finland +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

An open-label Phase 2a study to evaluate the safety and efficacy of AlloNK®, an allogeneic cord blood-derived NK cell therapy, in combination with rituximab in relapsing forms of B-cell dependent rheumatologic diseases

Portugal, Bulgaria, Germany, Spain, Romania, Italy +2 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Idiopathic Inflammatory Myopathies Iim trials by city

Idiopathic Inflammatory Myopathies Iim clinical trials

Recruiting idiopathic inflammatory myopathies iim studies right now

A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases

Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)

Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.

Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases

Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy

Safety Study of CC312 in Autoimmune Disease Patients

MTS109 in Patients With Refractory Autoimmune Diseases

A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases

Also recruiting in Europe

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Nipocalimab in Participants with Active Idiopathic Inflammatory Myopathies

A Phase 2, randomized, open-label, controlled study to evaluate the efficacy and safety of rapcabtagene autoleucelversus comparator in participants with severe refractory idiopathic inflammatory myopathies

An open-label Phase 2a study to evaluate the safety and efficacy of AlloNK®, an allogeneic cord blood-derived NK cell therapy, in combination with rituximab in relapsing forms of B-cell dependent rheumatologic diseases

Idiopathic Inflammatory Myopathies Iim trials by city

Other conditions